Therapies responsive to neoadjuvant chemotherapy, exemplified by CREATE-X and KATHERINE Trial, are becoming mainstream, especially for TNBC and HER2-positive breast cancer subtypes [24–26]. Here, ERBB2 is linked to breast cancer.